To the Editor A recent Review offered a comprehensive overview of endometrial cancer, highlighting the emerging significance of molecular classification in informing prognosis and treatment, which reflects the growing role of molecular classification in clinical care. Nevertheless, the practical implementation of molecular classification was inadequately explored. Access to comprehensive molecular testing is inconsistent across health care systems. Even in high-resource settings, the availability of assays such as polymerase epsilon (POLE) sequencing is variable and result interpretation lacks standardization. These challenges are more pronounced in low-resource settings, resulting in a disparity between theoretical optimal care and real-world clinical practice.